Eye-protecting DHA-lutein ester, and preparation method therefor and use thereof

By synthesizing DHA and lutein into DHA-lutein ester, the instability and low bioavailability of lutein are solved, and a new compound is formed, which improves the retinal protection effect and significantly improves vision and eyesight synergy of health.

WO2024240014A1PCT designated stage expired Publication Date: 2024-11-28OCEAN UNIV OF CHINA +1
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/092972
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-24
Filing Date
2024-05-14
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

The instability and low bioavailability of lutein in high temperature and strong light limits its application in functional foods, affecting its effectiveness in protecting vision and promoting eye health.

Method used

DHA and lutein are synthesized into DHA-lutein esters, which improves its stability through phenolic hydroxy esterification, and decomposes into lutein and DHA in vivo through monoester or diester forms, improving bioavailability and synergistic effects.

Benefits of technology

It significantly improves the retinal macular pigment density, protects retinal cells, enhances the health protection effect of eye, and avoids the low activity of lutein and DHA in the body and prone to oxidation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024092972_28112024_PF_FP_ABST
    Figure CN2024092972_28112024_PF_FP_ABST
Patent Text Reader

Abstract

A DHA-lutein ester, and a preparation method therefor and a use thereof. The DHA-lutein ester is a lutein monoester and / or a lutein diester, and can be used in preparation of products capable of stable and efficient eye protection and vision improvement. By synthesizing DHA and lutein into a DHA-lutein ester, not only the stability and bioavailability of lutein are improved, but also the advantages of DHA and lutein are integrated, and DHA synergistically assists lutein in acting in the macula of the retina, thereby protecting eye health and improving vision. The DHA-lutein ester can be further prepared into an oil suspension and microcapsule powder for use in the fields of food additives, dietary supplements, pet food and the like, and has a good application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Eye-protecting DHA-lutein ester and its preparation method and application Technical Field

[0001] The present invention belongs to the technical field of application of medicines / health products (functional foods) in the medical field, and specifically relates to an eye-protecting lutein ester and a preparation method and application thereof. Background Art

[0002] The retina, as a receptor for light signals, plays a crucial role in vision. Light reaching the retina forms visual images. Prolonged, intense visible light stimulation can damage retinal photoreceptor cells. This damage can progress to apoptosis and vision loss, but this "retinal photodamage" may resolve with functional recovery. With technological advancements, people are increasingly exposed to artificial light sources (e.g., LED lights, mobile phones, computers, and other devices). Photochemical damage caused by shorter wavelengths of visible light (400–550 nm, such as blue light) is the most important and prevalent form of retinal photodamage and is currently a research focus. Studies have shown that excessive exposure to blue light significantly increases reactive oxygen species production, leading to photoreceptor loss, lipid peroxidation, and apoptosis. The synergistic effects of blue light and N-retinylethanolamine (A2E), as well as photoreversal of photobleaching, further exacerbate photochemical damage, triggering inflammatory responses, DNA damage, and inhibition of mitochondrial and lysosomal function. In particular, blue light not only harms the retina but also damages the ocular surface through oxidative stress and inflammatory responses, significantly impacting age-related macular degeneration and myopia. Many eye diseases are the result of the long-term combined effects of multiple factors. In addition to conventional surgical treatment and developing good eye habits, improving diet is also an important approach to improving vision and addressing eye diseases. Therefore, protecting eye health and improving vision through dietary supplements or functional foods is gaining increasing attention.

[0003] Lutein is the primary carotenoid in the human macula and retina, found widely in plants such as marigold, pumpkin, and cabbage. It has biological activities such as preventing brain aging, protecting vision, alleviating visual fatigue, and promoting eye health. Lutein protects the retina primarily through two pathways: one is through its reducing properties, inactivating singlet oxygen and capturing reactive oxygen free radicals, thereby protecting photosensitive cells; the other is through its blue light filtering effect, preventing blue light from reaching the underlying retinal structures, thereby reducing the risk of light-induced oxidative damage. In addition, some studies have shown that lutein intake through diet or as a nutritional supplement has beneficial effects on eye diseases. However, its low bioavailability and instability under high temperatures and strong light limit its use in functional foods. Lutein esters are a naturally occurring form of lutein, formed by esterifying lutein with one or two fatty acids (such as myristic acid, lauric acid, and palmitic acid), and are a safe source of lutein. Lutein esters are absorbed into the body and enter the small intestine where they are hydrolyzed by trypsin into free fatty acids and lutein. Under the emulsification of bile, lutein forms mixed micelles with fatty acids, bile salts and other components and enters the lymph and blood.

[0004] Docosahexaenoic acid (DHA) is a marine-derived dietary ω-3 long-chain polyunsaturated fatty acid with biological activities such as anti-inflammatory, antioxidant, cardiovascular disease prevention, and neuronal development promotion. It is also the primary structural lipid in the outer segment membranes of retinal photoreceptors. Tissue DHA status influences the signaling mechanisms of retinal cells involved in phototransduction and can affect retinal function by altering permeability, fluidity, thickness, and lipid phase properties. Furthermore, DHA may play a role in signaling cascades that enhance the activation of membrane-bound retinal proteins and participate in rhodopsin regeneration. In some cases, DHA supplementation can improve visual processing deficits, but its susceptibility to oxidation affects product quality.

[0005] Summary of the Invention

[0006] The technical problem to be solved by the present invention is that lutein has biological activities such as protecting eyesight, relieving visual fatigue and promoting eye health, but its low bioavailability and instability under high temperature and strong light limit its application in functional foods.

[0007] To solve the above problems, the present invention provides an eye-protecting DHA-lutein ester and its preparation method and application. DHA and lutein are synthesized into DHA-lutein ester, which not only improves the stability and bioavailability of lutein, but also combines the advantages of both. DHA synergistically assists lutein in the retinal macular area, thereby protecting eye health and improving vision.

[0008] To achieve the above object, the present invention is implemented by the following technical solution: an eye-protecting DHA-lutein ester, the structural formula of the compound is shown below:

[0009] and / or

[0010] Among them, R stands for DHA.

[0011] The present invention introduces DHA into lutein compounds. After the phenolic hydroxyl groups in lutein are esterified, the stability of the compound is increased to form a new type of lutein ester derivative, thereby improving the problem of DHA being easily oxidized.

[0012] The combination of DHA and lutein can improve the macular pigment optical density in the human body more than using lutein alone, protect human retinal pigment epithelial cells (RPE cells) from the attack of reactive oxygen and increase the lutein level in plasma. DHA can also promote the accumulation of lutein in the blood and macula, and has a synergistic effect with lutein in protecting eye health. But when supplementing lutein and DHA separately, a large part of the two will be excreted in the process of entering the body, and only a small part can enter the body and continue to play a physiological role. The bioavailability and stability of lutein obtained by decomposing lutein esters are higher than free lutein, and are more conducive to the utilization of intestinal microorganisms (such as bifidobacteria and lactobacilli, etc.), alleviate the symptoms of oxidative stress, significantly improve retinal macular pigment density, and improve eye function.

[0013] The compound of the present invention can bring more lutein and DHA into the body in the form of monoester, and then decompose into lutein and DHA in the body to take effect, thereby solving the problems of low activity, rapid metabolism and low bioavailability of lutein in the body.

[0014] The diester form of the compound of the present invention can change the intestinal microbial structure, increase the abundance of beneficial bacteria such as bifidobacteria and lactobacilli, regulate the metabolites of the bacterial flora and thus alleviate the symptoms of oxidative stress, thereby significantly increasing the retinal macular pigment density.

[0015] Therefore, the compound of the present invention can not only exert the synergistic effect of DHA and lutein in protecting eye health and improving vision, but also avoid the shortcomings of lutein such as low activity in the body, rapid metabolism and low bioavailability, and easy oxidation of DHA.

[0016] Furthermore, the DHA-lutein ester is one or a mixture of more than one of lutein monoester and lutein diester.

[0017] Furthermore, the DHA content of the DHA-lutein ester is 30-60%.

[0018] Furthermore, the DHA-lutein ester can be used in the preparation of stable and efficient eye protection and vision improvement products.

[0019] Furthermore, the product contains the above-mentioned lutein ester at a pharmacologically effective concentration (1% to 100%).

[0020] Furthermore, the product is a medicine or a biological preparation, and the medicine is taken orally.

[0021] Furthermore, the product is a food, a food for special medical purposes, a health product, a functional food or a dietary supplement. The functional food includes milk, a beverage or a baked product.

[0022] The present invention also discloses a method for preparing the above-mentioned eye-protecting DHA-lutein ester, comprising the following steps:

[0023] (1) Lutein and free DHA were weighed, and dichloromethane, a catalyst 4-dimethylaminopyridine (DMAP) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) were added, nitrogen was filled, and the mixture was shaken in a water bath; after the reaction, the reaction mixture was transferred to a beaker, dichloromethane was added, and then washed with dilute hydrochloric acid solution, saturated sodium bicarbonate solution, and saturated sodium chloride solution in sequence; the organic phase was recovered and vacuum evaporated until no dichloromethane was present to obtain a crude DHA-lutein ester product, which contained two types of compounds, monoester and diester, and the reaction degree was above 90%;

[0024] (2) After the silica gel is activated, it is fully dissolved with n-hexane and then loaded into a silica gel column; the crude product is then dissolved with n-hexane and slowly poured into a silica gel column, and eluted with n-hexane and a mixed reagent of n-hexane-acetone solution in sequence, and the eluate is collected. During the elution process, the separation of lutein monoester and lutein diester is determined by thin layer silica gel plate chromatography, and the eluates of lutein monoester and diester are collected respectively, and concentrated under reduced pressure at low temperature and in the dark to collect lutein monoester and diester respectively.

[0025] Furthermore, other inert gases may be used in the nitrogen-filled reaction conditions in step (1).

[0026] Furthermore, step (1) is shaken in a water bath at 25°C to 30°C, and the reaction time is 1 to 8 hours.

[0027] Furthermore, in step (2), the crude product is eluted sequentially with n-hexane, a n-hexane-acetone solution with a volume ratio of 9:1, and a n-hexane-acetone solution with a volume ratio of 8:2. A certain column volume of n-hexane eluent, 5 column volumes of an n-hexane-acetone solution eluent with a volume ratio of 9:1, and an n-hexane-acetone solution eluent with a volume ratio of 8:2 are obtained, respectively. The eluent with the n-hexane-acetone solution with a volume ratio of 9:1 contains lutein diesters, and the eluent with the n-hexane-acetone solution with a volume ratio of 8:2 contains lutein monoesters.

[0028] Furthermore, in step (1), the added amounts of DMAP and EDCI are both 0.2-2 g / g lutein, the added amount of DHA is 1.5-3 g / g lutein, and the concentration of lutein in the solvent is 5-100 mg / mL.

[0029] Specifically, the present invention is as follows:

[0030] 1. A DHA-lutein ester having the following structural formula:

[0031] and / or

[0032] Among them, R stands for DHA.

[0033] 2. The DHA-lutein ester according to item 1, wherein the DHA content of the DHA-lutein ester is 30-60%.

[0034] 3. The DHA-lutein ester according to claim 1, wherein the DHA-lutein ester is prepared by the following method:

[0035] Lutein and free DHA are added to dichloromethane, catalyst DMAP and EDCI, and reacted under an inert gas atmosphere to obtain the product.

[0036] 4. The DHA-lutein ester according to claim 3, wherein the added amounts of DMAP and EDCI are both 0.2-2 g / g lutein, the added amount of DHA is 1.5-3 g / g lutein, and the concentration of lutein in the solvent is 5-100 mg / mL.

[0037] 5. The DHA-lutein ester according to item 3, characterized in that the reaction conditions for preparing the DHA-lutein ester are shaking in a water bath at 30°C and a reaction time of 1 to 8 hours.

[0038] 6. The DHA-lutein ester according to claim 3, wherein the DHA-lutein ester is purified by the following method:

[0039] 1) adding dichloromethane to the reaction mixture, and then washing with dilute hydrochloric acid solution, saturated sodium bicarbonate solution, and saturated sodium chloride solution in sequence, and recovering the organic phase;

[0040] 2) rotary evaporation under reduced pressure until no dichloromethane is removed, thereby obtaining a crude DHA-lutein ester product;

[0041] 3) After activation, the silica gel was fully dissolved with n-hexane and loaded into a silica gel column. The crude product obtained in step 2) was then dissolved with n-hexane and slowly poured into the silica gel column. The column was eluted with n-hexane and then a mixed reagent of n-hexane-acetone solution, and the eluate was collected;

[0042] 4) Concentrate under reduced pressure at low temperature and in the dark.

[0043] 7. The DHA-lutein ester according to claim 6, wherein:

[0044] Step 3) eluting with n-hexane, a n-hexane-acetone solution with a volume ratio of 9:1, and a n-hexane-acetone solution with a volume ratio of 8:2, respectively collecting the eluates of lutein diester and lutein monoester;

[0045] Step 4) Concentrating under reduced pressure at low temperature and in the dark to obtain lutein diester and lutein monoester, respectively.

[0046] 8. The method for preparing the DHA-lutein ester according to item 1, comprising the following steps:

[0047] Lutein and free DHA are added to dichloromethane, catalyst DMAP and EDCI, and reacted under an inert gas atmosphere to obtain the product.

[0048] 9. The method for preparing DHA-lutein ester as described in item 8, characterized in that the added amount of DMAP and EDCI is 0.2-2 g / g lutein, the added amount of DHA is 1.5-3 g / g lutein, and the concentration of lutein in the solvent is 5-100 mg / mL.

[0049] 10. The method for preparing DHA-lutein ester according to item 8, characterized in that the reaction conditions are shaking in a water bath at 30°C and the reaction time is 1 to 8 hours.

[0050] 11. The method for preparing DHA-lutein ester according to claim 8, wherein the purification method after preparation comprises the following steps:

[0051] 1) adding dichloromethane to the reaction mixture, and then washing with dilute hydrochloric acid solution, saturated sodium bicarbonate solution, and saturated sodium chloride solution in sequence, and recovering the organic phase;

[0052] 2) rotary evaporation under reduced pressure until no dichloromethane is removed, thereby obtaining a crude DHA-lutein ester product;

[0053] 3) After activation, the silica gel was fully dissolved with n-hexane and loaded into a silica gel column. The crude product obtained in step 2) was then dissolved with n-hexane and slowly poured into the silica gel column. The column was eluted with n-hexane and then a mixed reagent of n-hexane-acetone solution, and the eluate was collected;

[0054] 4) Concentrate under reduced pressure at low temperature and in the dark.

[0055] 12. The method for preparing DHA-lutein ester according to claim 11, characterized in that:

[0056] Step 3) eluting with n-hexane, a n-hexane-acetone solution with a volume ratio of 9:1, and a n-hexane-acetone solution with a volume ratio of 8:2, respectively collecting the eluates of lutein diester and lutein monoester;

[0057] Step 4) Concentrating under reduced pressure at low temperature and in the dark to obtain lutein diester and lutein monoester, respectively.

[0058] 13. A preparation comprising the DHA-lutein ester according to item 1.

[0059] 14. The preparation according to item 13, wherein the preparation is an oil suspension or microcapsule powder.

[0060] 15. The preparation according to claim 13, wherein the preparation comprises DHA-lutein ester at an effective concentration of 1% to 100%.

[0061] 16. The preparation according to item 13, wherein the purity of DHA-lutein ester in the preparation is above 90%.

[0062] 17. The preparation according to item 13, characterized in that the preparation is a medicine or a biological preparation and is used orally.

[0063] 18. The preparation according to claim 13, wherein the preparation is a food, a special medical food, a health product, a functional food, a dietary supplement, a food additive, a pet food, or a pet food additive.

[0064] 19. Use of the DHA-lutein ester described in item 1 in the preparation of stable and efficient eye protection and vision improvement products.

[0065] 20. The use according to item 19, wherein the product is an oil suspension or microcapsule powder.

[0066] 21. The use according to item 19, wherein the product contains DHA-lutein ester at an effective concentration of 1% to 100%.

[0067] 22. The use according to item 19, wherein the purity of DHA-lutein ester in the product is above 90%.

[0068] 23. The use as described in item 19, characterized in that the product is a medicine or a biological preparation, and is used orally.

[0069] 24. The use according to item 19, wherein the product is a food, a special medical food, a health product, a functional food, a dietary supplement, a food additive, a pet food, or a pet food additive.

[0070] The beneficial effects of the present invention are:

[0071] (1) The present invention uses lutein and free DHA as raw materials to prepare DHA-lutein ester, which is further separated and purified to obtain a purity of more than 90%.

[0072] (2) The preparation method provided by the present invention has low cost, simple steps, uses a small amount of organic solvent, and generates little organic solvent pollution to the environment.

[0073] (3) Animal experiments have shown that the lutein ester product prepared by the inventive method has better eye protection effect than lutein alone, and can be further prepared into oil suspension and microcapsule powder for use in food additives, dietary supplements, pet food and other fields, with good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0074] FIG1 is a thin layer chromatogram of the crude reaction product components of the present invention;

[0075] Figure 2 is a HPLC chromatogram of free lutein standard and purified reaction product.

[0076] Among them, (a) is free lutein, (b) is DHA-lutein monoester, and (c) is DHA-lutein diester. DETAILED DESCRIPTION

[0077] To make the objectives, technical solutions, and advantages of the embodiments of the present invention more clear, the technical solutions in the embodiments of the present invention are clearly and completely described below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.

[0078] Unless otherwise specified, the materials and reagents used in the following examples were commercially available.

[0079] Example 1: Preparation of DHA-lutein ester

[0080] 500mg of lutein, 1200mg of DHA, 800mg of EDCI, and 200mg of DMAP were weighed and placed in 5mL of dichloromethane, purged with nitrogen, and shaken in a 25°C water bath for 1 hour. After the reaction, the reaction mixture was transferred to a beaker and washed with 10mL of dichloromethane, 100mL of dilute hydrochloric acid, 100mL of saturated sodium bicarbonate solution, and 100mL of saturated sodium chloride solution. The organic phase was separated and the organic solvent was removed by rotary evaporation under reduced pressure until no dichloromethane was present. The crude DHA-lutein ester product, containing both monoester and diester compounds, was obtained, with a reaction rate of over 90%.

[0081] Silica gel column chromatography was used for separation and purification. After activation, the silica gel was fully dissolved in n-hexane and loaded onto the silica gel column. The crude product was then dissolved in n-hexane and slowly poured into the silica gel column. Elution was performed sequentially with n-hexane, a mixture of n-hexane / acetone (90 / 10), and n-hexane / acetone (80 / 20), and the eluate was collected. During the elution process, the eluate was subjected to thin-layer silica gel plate chromatography to determine the separation of lutein diesters and lutein monoesters, and the eluates of lutein diesters and lutein monoesters were collected separately.

[0082] The mixture was concentrated under reduced pressure at low temperature and in the dark, dried to remove dichloromethane, and stored in the dark at -20°C. The eluate from n-hexane / acetone (90 / 10) was the lutein diester solution; the eluate from n-hexane / acetone (80 / 20) was the lutein monoester solution.

[0083] Example 2: Detection of DHA-lutein esters

[0084] 1. Methods

[0085] 1.1 Thin layer chromatography detection

[0086] The crude product of Example 1 was preliminarily analyzed by thin-layer chromatography using a 4:1 by volume n-hexane-acetone solution as the developing solvent. 10 ml of the developing solvent was added to a chromatography cylinder, which was sealed and equilibrated for 30 minutes. Samples were then spotted using a 0.3 x 100 mm capillary tube, with the spotting line 1 cm from the bottom edge of the silica gel plate. This process was repeated multiple times, with the solvent being blown dry during the spotting process. When the solvent front was 1 cm from the top edge of the silica gel plate, the silica gel plate was removed and the color was allowed to develop naturally at room temperature.

[0087] 1.2 High-performance liquid chromatography detection

[0088] Chromatographic conditions: chromatographic column: YMC C30 (4.6 mm × 250 mm, 3 μm); mobile phase A: chromatographic grade methanol, mobile phase B: chromatographic grade methyl tert-butyl ether; gradient elution, flow rate 1.0 ml / min; detection wavelength 450 nm; column temperature: 30°C; injection volume: 10 μl.

[0089] 2. Experimental Results

[0090] 2.1. Thin layer chromatography results

[0091] The developing solvent used in Example 2 can separate free lutein, DHA-lutein monoester and DHA-lutein diester very well. The results of thin layer chromatography under natural color development are shown in Figure 1. Three bands appeared on the TLC plate, and the Rf values ​​were 0.90, 0.31 and 0.08, respectively. Referring to the bands of the free lutein standard, it can be seen that the band with an Rf value of 0.08 is free lutein. After the hydroxyl groups at both ends of lutein react with DHA for esterification, the polarity of the product decreases, and the polarity of the DHA-lutein diester substituted on both sides is smaller than that of the DHA-lutein monoester substituted on one side. Therefore, it is preliminarily judged that the band with an Rf value of 0.31 is DHA-lutein monoester, and the band with an Rf value of 0.90 is DHA-lutein diester.

[0092] 2.2 HPLC results

[0093] Figure 2 shows HPLC chromatograms of a lutein standard and the DHA-lutein monoester and diester obtained by column chromatography purification in Example 1. Figure 2(a) shows the chromatographic peak of the free lutein standard, with an elution time of 3-4 minutes; Figure 2(b) shows an elution time of 5-6 minutes, which, combined with the primary mass spectrometry, confirms that it is DHA-lutein monoester with an m / z of 897.4; Figure 2(c) shows an elution time of 11-12 minutes, which, combined with the primary mass spectrometry, confirms that it is DHA-lutein diester with an m / z of 1125.8. The YMC C30 column is a reversed-phase column, and compounds with high polarity elute first, while compounds with low polarity elute later. The elution time of the DHA-lutein monoester and diester is higher than that of the free lutein, indicating that the product has become less polar.

[0094] Example 3: Repairing effect of DHA-lutein ester on retinal damage caused by blue light

[0095] 1. Methods

[0096] 1.1 Preparation of oral emulsion

[0097] Purified lutein esters and free lutein were added to a mixture of 90% saline and 10% corn oil (wt / wt). Porcine bile salts (0.1%) were then added to the mixture. Cells were disrupted after sonication in an ice bath. The resulting emulsion, with a lutein equivalent concentration of 10 mg / ml, was administered orally to rats.

[0098] 1.2 Animal experiments

[0099] Seventy SD rats were adaptively fed for one week. Ten rats served as a control group and were not subjected to blue light damage. Sixty rats were anesthetized with an injection of sodium pentobarbital at a dose of 30 mg / kg body weight. The rats were then given compound tropicamide eye drops to dilate their pupils and subjected to strong blue light damage. After damage, they were randomly divided into six groups and gavaged with normal saline, lutein emulsion, normal saline with DHA, a mixed emulsion of DHA and lutein, DHA-lutein monoester emulsion, and DHA-lutein diester emulsion, respectively. These groups were designated as the model group, lutein group, DHA group, lutein + DHA group, DHA-lutein monoester group, and DHA-lutein diester group. Electroretinograms were measured after one week of continuous gavage.

[0100] 2. Results

[0101] Table 1 Amplitudes of a and b waves of rat electroretinogram Note: a, b, c, d, e, f with different letters indicate significant differences between the data (P < 0.05).

[0102] Table 1 shows the changes in the a and b wave amplitudes of the rat electroretinogram after one week of oral administration. The a wave primarily originates from the receptor potential of photoreceptors; the b wave, with a larger amplitude, is primarily related to bipolar cell activity. As can be seen from the table above, the a and b wave amplitudes significantly decreased after intense blue light exposure, indicating that the model was successfully established.

[0103] After administering DHA and lutein separately, the amplitudes of a and b waves increased, but the increase was much smaller than that of the DHA+lutein combination and DHA-lutein ester, indicating that the effect of DHA and lutein used in combination or synthesized into lutein ester is significantly better than that of the two used alone. The increase in the amplitudes of a and b waves of DHA-lutein ester is significantly higher than that of the DHA+lutein combination, indicating that the DHA-lutein ester obtained by the present invention has good blue light protection and eye health protection effects. Among them, the increase in the amplitudes of a and b waves of the DHA-lutein diester group is significantly higher than that of the DHA-lutein monoester group, and the effect of DHA-lutein diester is better.

[0104] Example 4: Effect of DHA-lutein ester on vision improvement in myopic animals

[0105] 1. Methods

[0106] 1.1 Preparation of oral emulsion

[0107] Purified lutein esters and free lutein were added to a mixture of 90% saline and 10% corn oil (wt / wt). Porcine bile salts (0.1%) were then added to the solution. Cells were disrupted after sonication in an ice bath. The resulting emulsion, with a lutein equivalent concentration of 10 mg / ml, was administered orally to young rabbits.

[0108] 1.2 Animal experiments

[0109] The experiment involved seven groups of five rabbits each: a control group, a model group, and five experimental groups (lutein, DHA, DHA + lutein, DHA-lutein monoester, and DHA-lutein diester). The rabbits in the model and five experimental groups were housed in tightly covered cages with thick floral fabric facing inward. The cages were then lined with thick floral fabric to create a grid of squares, each sized to accommodate one rabbit at the outset. The rabbits were free to move, so their initial visual range (depth) was generally no more than 5-10 cm. As the rabbits grew, the cage size and grid size were gradually increased, but the visual range was maintained at approximately 5-10 cm. To force the rabbits to use their eyes at close range, the feed was finely chopped and mixed with twice the amount of gravel, from which they were allowed to select their food. During the suckling period, the feeding bottle, feeding trough, and water pitcher were placed outside a grid in a cage covered with thick floral fabric, forcing the rabbits to stretch their heads out to eat and drink. To provide multiple stimulations and force the rabbits to use their eyes more, the positions of the feeding bottle, feeding trough, and water pitcher were rotated every 3-5 days to train the rabbits in each experimental group to visually select food. The cages of the five rabbits in the control group were uncovered, and no visual stimulation or visual distance restriction measures were used. At 25 weeks of age, the pupils were dilated with 1% atropine solution, and then the eyelids were opened with a homemade eyelid dilator. The diopter (D) of each rabbit's left and right eye was measured using a computerized optometry system. The naked eye foraging distance (cm) and body weight (g) were also measured with a tape measure.

[0110] After successful modeling, the emulsion was administered orally for one month. During this period, the rabbits in each group were housed in enclosures under the same natural light and environment. The eyelids, conjunctiva, cornea, limbus, anterior chamber, and iris were observed daily, and a comprehensive slit lamp examination was performed once a week. Treatment results were then measured using computer optometry and statistically analyzed using the aforementioned method.

[0111] result

[0112] Tables 2 and 3 show the results of the myopic rabbit model at 25 weeks of the experiment and the changes in diopter, foraging distance, and weight of the rabbits after one month of gavage. As can be seen from the table, rabbits exposed to restricted viewing distance and dim light during their growth period are only able to see close up and have no need to see far away. Furthermore, they are required to select food at close range for extended periods. This objectively forces the eyes to develop an adaptive near-sightedness, resulting in a decrease in myopic diopter (D) during computer testing, successfully establishing the myopia model.

[0113] After administration, the refractive index of the experimental groups increased. With the improvement or enhancement of vision, coupled with the improvement of the growth environment, the growth and development of young rabbits are promoted and the distance of naked eye foraging response is increased. The increase in refractive index of the DHA-lutein monoester group and the lutein diester group is much greater than that of the other groups, indicating that DHA-lutein ester has a significant effect on improving vision. Although there is no significant difference in the results between the DHA-lutein monoester group and the DHA-lutein diester group, the refractive index (D) and foraging distance of the DHA-lutein diester group are higher than those of the DHA-lutein monoester group, and the effect of DHA-lutein diester is better.

[0114] Table 2 Results of the myopic rabbit model study at 25 weeks of the experiment

[0115] Table 3 Comparative study on the effects of myopic rabbits treated for 30 days Note: a, b, c, d with different letters indicate significant differences between the data (P < 0.05).

[0116] In summary, the preparation of DHA-lutein ester using DHA and lutein as raw materials can better protect against blue light, protect eye health, and improve vision, and has good application prospects.

[0117] The above describes the specific embodiments of the present invention. It should be understood that the present invention is not limited to the above specific embodiments, and those skilled in the art may make various variations or modifications within the scope of the claims, which do not affect the essence of the present invention.

Claims

1. A DHA-lutein ester, the structural formula of which is as follows: and / or Among them, R stands for DHA.

2. The DHA-lutein ester according to claim 1, characterized in that: The DHA content of the DHA-lutein ester is 30-60%.

3. The DHA-lutein ester according to claim 1, wherein the DHA-lutein ester is prepared by the following method: Lutein and free DHA are taken, dichloromethane, catalyst DMAP and EDCI are added, and the mixture is reacted under an inactive gas atmosphere to obtain the product.

4. The DHA-lutein ester according to claim 3, characterized in that: The added amounts of DMAP and EDCI are both 0.2-2 g / g lutein, the added amount of DHA is 1.5-3 g / g lutein, and the concentration of lutein in the solvent is 5-100 mg / mL.

5. The DHA-lutein ester according to claim 3, characterized in that: The reaction conditions for preparing DHA-lutein ester are shaking in a water bath at 30° C. and a reaction time of 1 to 8 hours.

6. The DHA-lutein ester according to claim 3, characterized in that The DHA-lutein ester is purified by the following method: 1) adding dichloromethane to the reaction mixture, and then washing with dilute hydrochloric acid solution, saturated sodium bicarbonate solution, and saturated sodium chloride solution in sequence, and recovering the organic phase; 2) Vacuum evaporation under reduced pressure until no dichloromethane is left, thereby obtaining a crude product of DHA-lutein ester; 3) After the silica gel is activated, it is fully dissolved with n-hexane and then loaded into a silica gel column. The crude product obtained in step 2) is then dissolved with n-hexane and slowly poured into the silica gel column. It is eluted with n-hexane and a mixed reagent of n-hexane-acetone solution in sequence, and the eluate is collected; 4) Concentrate under reduced pressure at low temperature and away from light.

7. The DHA-lutein ester according to claim 6, characterized in that: Step 3) eluting with n-hexane, a n-hexane-acetone solution with a volume ratio of 9:1, and a n-hexane-acetone solution with a volume ratio of 8:2, respectively collecting the eluates of lutein diester and lutein monoester; Step 4) Concentrating under reduced pressure at low temperature and in the dark to obtain lutein diester and lutein monoester respectively.

8. The method for preparing DHA-lutein ester according to claim 1, comprising the following steps: Lutein and free DHA are taken, dichloromethane, catalyst DMAP and EDCI are added, and the mixture is reacted under an inactive gas atmosphere to obtain the product.

9. The method for preparing DHA-lutein ester according to claim 8, characterized in that: The added amounts of DMAP and EDCI are both 0.2-2 g / g lutein, the added amount of DHA is 1.5-3 g / g lutein, and the concentration of lutein in the solvent is 5-100 mg / mL.

10. The method for preparing DHA-lutein ester according to claim 8, characterized in that: The reaction conditions are shaking in a water bath at 30°C and the reaction time is 1 to 8 hours.

11. The method for preparing DHA-lutein ester according to claim 8, wherein the purification method after preparation comprises the following steps: 1) adding dichloromethane to the reaction mixture, and then washing with dilute hydrochloric acid solution, saturated sodium bicarbonate solution, and saturated sodium chloride solution in sequence, and recovering the organic phase; 2) Vacuum evaporation under reduced pressure until no dichloromethane is left, thereby obtaining a crude product of DHA-lutein ester; 3) After the silica gel is activated, it is fully dissolved with n-hexane and then loaded into a silica gel column. The crude product obtained in step 2) is then dissolved with n-hexane and slowly poured into the silica gel column. It is eluted with n-hexane and a mixed reagent of n-hexane-acetone solution in sequence, and the eluate is collected; 4) Concentrate under reduced pressure at low temperature and away from light.

12. The method for preparing DHA-lutein ester according to claim 11, characterized in that: Step 3) eluting with n-hexane, a n-hexane-acetone solution with a volume ratio of 9:1, and a n-hexane-acetone solution with a volume ratio of 8:2, respectively collecting the eluates of lutein diester and lutein monoester; Step 4) Concentrating under reduced pressure at low temperature and in the dark to obtain lutein diester and lutein monoester respectively.

13. A preparation comprising the DHA-lutein ester of claim 1.

14. The preparation according to claim 13, characterized in that: The preparation is an oil suspension or microcapsule powder.

15. The preparation according to claim 13, characterized in that: The preparation contains DHA-lutein ester in an effective concentration of 1% to 100%.

16. The preparation according to claim 13, characterized in that: The purity of DHA-lutein ester in the preparation is above 90%.

17. The preparation according to claim 13, characterized in that: The preparation is a medicine or a biological preparation and is used orally.

18. The preparation according to claim 13, characterized in that: The preparation is food, special medical food, health product, functional food, dietary supplement, food additive, pet food or pet food additive.

19. Use of the DHA-lutein ester according to claim 1 in the preparation of a stable and efficient eye protection and vision improvement product.

20. The use according to claim 19, characterized in that: The product is an oil suspension or microcapsule powder.

21. The use according to claim 19, characterized in that: The preparation contains DHA-lutein ester in an effective concentration of 1% to 100%.

22. The use according to claim 19, characterized in that: The purity of DHA-lutein ester in the product is above 90%.

23. The use according to claim 19, characterized in that: The product is a medicine or a biological preparation and is used orally.

24. The use according to claim 19, characterized in that: The product is food, special medical food, health product, functional food, dietary supplement, food additive, pet food or pet food additive.

Citation Information

Patent Citations

  • Lutein ester health care product for protecting eyesight and preparation method thereof

    CN102144780A

  • Eye care preparation and preparation method thereof

    CN104839688A

  • Edible blend oil containing lutein ester and preparation method thereof

    CN111513145A

  • Eye-protecting DHA-lutein ester as well as preparation method and application thereof

    CN116621749A

  • Stabilized esters of lutein

    WO2008023283A2